The report analyzes and forecasts the inflammatory bowel disease treatment market at global and regional levels. The market has been forecast based on volume (Tons) and value (US$ Mn) from 2019 to 2026. The study includes drivers and restraints of the global market. It covers the impact of these drivers and restraints on the demand during the forecast period. The report also highlights opportunities in the market at the global level. For the region and all segments, the sales, revenue and their market share, growth rate are key research objects; we can research the manufacturers' sales, price, revenue, cost and gross profit and their changes. What's more, we will display the main consumers, raw material manufacturers, distributors, etc.
This report first introduces the background of inflammatory bowel disease treatment, including the definition, classification, application, industrial chain structure, industry overview, national policy and planning analysis of the industry, and the latest dynamic analysis. With regard to production bases and technologies, the research in this report covers the production time, base distribution, technical parameters, research and development trends, technology sources, and sources of raw materials of major inflammatory bowel disease treatment companies.
Regarding the analysis of the industry chain, the research of this report covers the raw materials and equipment of inflammatory bowel disease treatment upstream, downstream customers, marketing channels, industry development trends and investment strategy recommendations. The more specific analysis also includes the main application areas of inflammatory bowel disease treatment and consumption, major regions and consumption, major global producers, distributors, raw material suppliers, equipment providers and their contact information, industry chain relationship analysis.
The report comprises a detailed value chain analysis, which provides a comprehensive view of the global inflammatory bowel disease treatment market. The Porter’s Five Forces model has also been included to help understand the competitive landscape of the market. The study encompasses market attractiveness analysis, wherein various applications have been benchmarked based on their market size, growth rate, and general attractiveness.
The study provides a decisive view of the inflammatory bowel disease treatment market by segmenting it in terms of form and application. The segment has been analyzed based on the present and future trends. Regional segmentation includes the current and projected demand in North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
The report provides size (in terms of volume and value) of inflammatory bowel disease treatment market for the base year 2018 and the forecast between 2019 and 2026. Market numbers have been estimated based on form and application. Market size and forecast for each application segment have been provided for the global and regional market.
Competitive Outlook
The competition matrix section included in the report is likely to assist the existing players to increase their market shares and new companies to establish their presence in the global inflammatory bowel disease treatment market. The report also profiles major players in the market based on various attributes such as company overview, financial overview, SWOT analysis, key business strategies, product portfolio, and recent developments. Major players operating in the inflammatory bowel disease treatment market include Shire Plc., Valeant Pharmaceuticals International, Inc., Allergan plc, Pfizer, Inc., Janssen Biotech, Inc. (Johnson & Johnson), Takeda Pharmaceutical Company Limited., AbbVie, Inc., Novartis AG, UCB Inc., and Biogen Inc.
Global Inflammatory Bowel Disease Treatment Market is segmented as given below:
Global Inflammatory Bowel Disease Treatment Market, by Drug Class
Global Inflammatory Bowel Disease Treatment Market, by Disease Indication
Global Inflammatory Bowel Disease Treatment Market, by Distribution Channel
Global Inflammatory Bowel Disease Treatment Market, by Geography
Research Methodology:
In-depth interviews and discussions were conducted with several key market participants and opinion leaders to compile the research report.
Primary research represents a bulk of research efforts, supplemented by extensive secondary research. Annual reports, press releases, and relevant documents of key players operating in various application areas have been reviewed for competition analysis and market understanding.
Secondary research also includes recent trends, technical writing, Internet sources, and statistical data from government websites, trade associations, and agencies. These have proved to be reliable, effective, and successful approaches for obtaining precise market data, capturing market participants’ insights, and recognizing business opportunities.
The study objectives of this report are:
Chapter 1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
Chapter 2. Assumptions and Research Methodology
Chapter 3. Executive Summary: Global Inflammatory Bowel Disease (IBD) Treatment market
Chapter 4. Market Overview
4.1. Introduction
4.2. Key Industry Developments
Chapter 5. Market Dynamics
5.1. Drivers
5.2. Restraints
5.3. Opportunities
5.4. Porter’s five forces analysis
5.5. Global Inflammatory Bowel Disease (IBD) Treatment Market Size (US$ Mn) Forecast, 2015–2026
5.6. Global Inflammatory Bowel Disease (IBD) Treatment Market Outlook
5.7. Global Prevalence of Ulcerative Colitis
5.8. Global Prevalence of Crohn’s Disease
5.9. Pipeline Analysis
Chapter 6. Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecast, by Drug Class
6.1. Key Findings
6.2. Introduction
6.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2026
6.3.1. TNF Inhibitors
6.3.2. Aminosalicyclates
6.3.3. Immunomodulators
6.3.4. Corticosteroids
6.4. Market Attractiveness Analysis, by Drug Class
6.5. Key Trends
Chapter 7. Global Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecasts, by Disease Indication
7.1. Key Findings
7.2. Introduction
7.3. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2026
7.3.1. Ulcerative Colitis
7.3.2. Crohn’s Disease
7.4. Market Attractiveness Analysis, by Disease Indication
7.5. Key Trends
Chapter 8. Global Inflammatory Bowel Disease (IBD) Treatment Market Analysis and Forecasts, by Distribution Channel
8.1. Key Findings
8.2. Introduction
8.3. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2026
8.3.1. Hospital Pharmacy
8.3.2. Retail Pharmacy
8.3.3. Online Pharmacy
8.4. Market Attractiveness Analysis, by Distribution Channel
8.5. Key Trends
Chapter 9. Global Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Global Market Scenario
9.3. Market Value (US$ Mn) Forecast, by Region, 2017-2026
9.3.1. North America
9.3.2. Europe
9.3.3. Asia Pacific
9.3.4. Latin America
9.3.5. Middle East & Africa
9.4. Market Attractiveness Analysis, by Region
9.5. Key Trends, By Region
Chapter 10. North America Inflammatory Bowel Disease (IBD) Treatment market Analysis andForecast
10.1. Key Findings
10.2. Market size (US$ Mn) Forecast, by Country, 2017-2026
10.2.1. U.S.
10.2.2. Canada
10.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2026
10.3.1. TNF Inhibitors
10.3.2. Aminosalicyclates
10.3.3. Immunomodulators
10.3.4. Corticosteroids
10.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2026
10.4.1. Ulcerative Colitis
10.4.2. Crohn’s Disease
10.5. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2026
10.5.1. Hospital Pharmacy
10.5.2. Retail Pharmacy
10.5.3. Online Pharmacy
10.6. Market Attractiveness Analysis
10.6.1. By Country
10.6.2. By Drug Class
10.6.3. By Disease Indication
10.6.4. By Distribution Channel
Chapter 11. Europe Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
11.1. Key Findings
11.2. Market size (US$ Mn) Forecast By Country/Sub-region, 2017-2026
11.2.1. Germany
11.2.2. U.K.
11.2.3. France
11.2.4. Italy
11.2.5. Spain
11.2.6. Rest of Europe
11.3. Market size (US$ Mn) Forecast, by Drug Class, 2017-2026
11.3.1. TNF Inhibitors
11.3.2. Aminosalicyclates
11.3.3. Immunomodulators
11.3.4. Corticosteroids
11.4. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2026
11.4.1. Ulcerative Colitis
11.4.2. Crohn’s Disease
11.5. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2026
11.5.1. Hospital Pharmacy
11.5.2. Retail Pharmacy
11.5.3. Online Pharmacy
11.6. Market Attractiveness Analysis
11.6.1. By Country/Sub-region
11.6.2. By Drug Class
11.6.3. By Disease Indication
11.6.4. By Distribution Channel
Chapter 12. Asia Pacific Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
12.1. Key Findings / Developments
12.2. Market Overview
12.3. Market size (US$ Mn) Forecast, by Country, 2017-2026
12.3.1. China
12.3.2. India
12.3.3. Japan
12.3.4. Australia & New Zealand
12.3.5. Rest of Asia Pacific
12.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2026
12.4.1. TNF Inhibitors
12.4.2. Aminosalicyclates
12.4.3. Immunomodulators
12.4.4. Corticosteroids
12.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2026
12.5.1. Ulcerative Colitis
12.5.2. Crohn’s Disease
12.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2026
12.6.1. Hospital Pharmacy
12.6.2. Retail Pharmacy
12.6.3. Online Pharmacy
12.7. Market Attractiveness Analysis
12.7.1. By Country/Sub-region
12.7.2. By Drug Class
12.7.3. By Disease Indication
12.7.4. By Distribution Channel
Chapter 13. Latin America Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
13.1. Key Findings / Developments
13.2. Market Overview
13.3. Market Size (US$ Mn) Forecast, by Country, 2017-2026
13.3.1. Brazil
13.3.2. Mexico
13.3.3. Rest of Latin America
13.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2026
13.4.1. TNF Inhibitors
13.4.2. Aminosalicyclates
13.4.3. Immunomodulators
13.4.4. Corticosteroids
13.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2026
13.5.1. Ulcerative Colitis
13.5.2. Crohn’s Disease
13.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2026
13.6.1. Hospital Pharmacy
13.6.2. Retail Pharmacy
13.6.3. Online Pharmacy
13.7. Market Attractiveness Analysis
13.7.1. By Country/Sub-region
13.7.2. By Drug Class
13.7.3. By Disease Indication
13.7.4. By Distribution Channel
Chapter 14. Middle East and Africa Inflammatory Bowel Disease (IBD) Treatment market Analysis and Forecast
14.1. Key Findings / Developments
14.2. Market Overview
14.3. Market size (US$ Mn) Forecast, by Country, 2017-2026
14.3.1. GCC Countries
14.3.2. South Africa
14.3.3. Rest of Middle East and Africa
14.4. Market size (US$ Mn) Forecast, by Drug Class, 2017-2026
14.4.1. TNF Inhibitors
14.4.2. Aminosalicyclates
14.4.3. Immunomodulators
14.4.4. Corticosteroids
14.5. Market size (US$ Mn) Forecast, by Disease Indication, 2017-2026
14.5.1. Ulcerative Colitis
14.5.2. Crohn’s Disease
14.6. Market size (US$ Mn) Forecast by Distribution Channel, 2017-2026
14.6.1. Hospital Pharmacy
14.6.2. Retail Pharmacy
14.6.3. Online Pharmacy
14.7. Market Attractiveness Analysis
14.7.1. By Country/Sub-region
14.7.2. By Drug Class
14.7.3. By Disease Indication
14.7.4. By Distribution Channel
Chapter 15. Competition Landscape
15.1. Global Inflammatory Bowel Disease (IBD) Treatment Market Share, by Company, 2016
15.2. Market Player – Competition Matrix (By Tier and Size of companies)
15.3. Company Profiles (Details – Overview, Financials, Recent Developments, Strategy)
15.3.1. Shire plc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
15.3.2. Pfizer, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Strategic Overview
15.3.3. Janssen Biotech, Inc. (Johnson & Johnson)
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.4. Valeant Pharmaceuticals International, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.5. Allergan plc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.6. Takeda Pharmaceutical Company Limited.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.7. AbbVie, Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.8. Novartis AG
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.9. UCB Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
15.3.10. Biogen Inc.
Company Overview (HQ, Business Segments, Employee Strength)
Product Portfolio
SWOT Analysis
Financial Overview
Strategic Overview
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers